Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS).
Expert Rev Vaccines. 2024 Jan-Dec;23(1):213-225. doi: 10.1080/14760584.2024.2310807. Epub 2024 Feb 8.
Expert Rev Vaccines. 2024.
PMID: 38288980
Free article.
Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS).
Maeda H, Saito N, Igarashi A, Ishida M, Suami K, Yagiuchi A, Kimura Y, Komino M, Arai H, Morikawa T, Motohashi I, Miyazawa R, Moriyama T, Kamura H, Terada M, Kuwamitsu O, Hayakawa T, Sando E, Ohara Y, Teshigahara O, Suzuki M, Morimoto K.
Maeda H, et al. Among authors: kuwamitsu o.
Clin Infect Dis. 2022 Nov 30;75(11):1971-1979. doi: 10.1093/cid/ciac292.
Clin Infect Dis. 2022.
PMID: 35438137
Free PMC article.
Item in Clipboard
Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS).
Maeda H, Saito N, Igarashi A, Ishida M, Terada M, Ito T, Ikeda H, Kamura H, Motohashi I, Kimura Y, Komino M, Arai H, Kuwamitsu O, Akuzawa N, Sando E, Morikawa T, Imura H, Inoue H, Hayakawa T, Teshigahara O, Ohara Y, Suzuki M, Morimoto K.
Maeda H, et al. Among authors: kuwamitsu o.
Expert Rev Vaccines. 2023 Jan-Dec;22(1):288-298. doi: 10.1080/14760584.2023.2188950.
Expert Rev Vaccines. 2023.
PMID: 36883371
Free article.
Item in Clipboard
Efficacy and safety of once-daily oxybutynin patch versus placebo and propiverine in Japanese patients with overactive bladder: A randomized double-blind trial.
Yamaguchi O, Uchida E, Higo N, Minami H, Kobayashi S, Sato H; Oxybutynin Patch Study Group.
Yamaguchi O, et al.
Int J Urol. 2014 Jun;21(6):586-93. doi: 10.1111/iju.12372. Epub 2013 Dec 18.
Int J Urol. 2014.
PMID: 24350662
Clinical Trial.
Item in Clipboard
Propiverine hydrochloride in Japanese patients with overactive bladder: a randomized, double-blind, placebo-controlled trial.
Gotoh M, Yokoyama O, Nishizawa O; Japanese Propiverine Study Group.
Gotoh M, et al.
Int J Urol. 2011 May;18(5):365-73. doi: 10.1111/j.1442-2042.2011.02732.x. Epub 2011 Feb 20.
Int J Urol. 2011.
PMID: 21332825
Clinical Trial.
Item in Clipboard
A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder.
Homma Y, Yamaguchi O; Imidafenacin Study Group.
Homma Y, et al.
Int J Urol. 2009 May;16(5):499-506. doi: 10.1111/j.1442-2042.2009.02286.x. Epub 2009 Mar 29.
Int J Urol. 2009.
PMID: 19389083
Clinical Trial.
Item in Clipboard
Bellini duct carcinoma of the kidney.
Miyamoto H, Kuwamitsu O, Moriyama M, Sakanishi S, Fujii H, Fukushima S, Sano J, Oaki Y.
Miyamoto H, et al. Among authors: kuwamitsu o.
Urol Int. 1992;48(4):460-2. doi: 10.1159/000282379.
Urol Int. 1992.
PMID: 1413315
Item in Clipboard
Cite
Cite